Quantcast

Latest PCSK9 Stories

2015-02-17 08:35:29

PCSK9 inhibitors could cost the health care system as much as $150 billion annually WOONSOCKET, R.I., Feb.

2015-01-09 00:21:04

Primary efficacy endpoints met in two trials of alirocumab administered every four weeks TARRYTOWN, N.Y. and PARIS, Jan. 9, 2015 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.

2014-11-18 16:26:22

Additional Data Analysis Showed Every Two Week and Monthly Dosing Regimens of Evolocumab Were Clinically Equivalent THOUSAND OAKS, Calif., Nov.

2014-11-12 16:28:54

Thirteen Presentations Include New Analyses of PCSK9 Inhibitor at Upcoming American Heart Association Scientific Sessions THOUSAND OAKS, Calif., Nov.

2014-11-10 08:34:30

THOUSAND OAKS, Calif., Nov. 10, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S.

heart attack protein
2014-09-04 03:00:00

A team of researchers at the University of Ottawa Heart Institute, led by Dr. Alexandre Stewart, have uncovered an intriguing link between heart attacks and a protein that is of great interest to drug companies for its impact on cholesterol.

2014-08-28 08:28:27

Represents First BLA Submission for a PCSK9 Inhibitor THOUSAND OAKS, Calif., Aug.

2014-03-27 04:20:44

Companies to Host Investor Conference Call on Alirocumab on March 31 at 9 AM EDT PARIS and TARRYTOWN, N.Y., March 27, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY)


Word of the Day
deuteragonist
  • A person in a secondary role, specifically the second most important character (after the protagonist).
The word 'deuteragonist' comes from a Greek word meaning 'an actor of second-class parts'.
Related